Artrya Limited (AU:AYA)
ASX:AYA
Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.10
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$4.10
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.61 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$759.05M
Enterprise ValueAU$517.34M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding161,156,620
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside48.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)AU$6.45M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetReported low leverage and an improving debt-to-equity (~0.03 in FY2025) provide durable financial flexibility. Modest borrowings reduce refinancing risk and interest burden, allowing the company to fund continued R&D, clinical validation, and early commercialization efforts without immediate debt pressure.
Early Revenue TractionRecognition of A$28k revenue in FY2025 after near-zero prior sales, and reported 123% revenue growth, indicate initial commercial traction. While absolute sales are small, the positive trend validates early product-market fit and creates a foundation to scale clinical adoption and commercial channels over the medium term.
Focused AI Cardiovascular ProductA focused product strategy targeting coronary angiography analytics addresses a structural need in cardiology workflows. Specialization in cardiovascular imaging can build domain expertise, facilitate clinical partnerships and integration into hospital systems, and support durable competitive differentiation as adoption grows.
Bears Say
Persistent Cash BurnConsistently negative operating and free cash flow show the business is cash-consuming. Persistent cash burn necessitates ongoing external funding, increases dilution risk, constrains the pace of commercial scaling and clinical studies, and creates a material funding dependency over the next several quarters.
Material Operating LossesDeep and sustained operating losses with extremely weak margins mean the company has not demonstrated scalable unit economics or a clear path to breakeven. Without meaningful revenue growth or operating leverage, profitability timelines remain uncertain, limiting reinvestment capacity and strategic optionality.
Equity Erosion And Negative ROEDeclining equity and a negative ROE reflect cumulative value erosion from ongoing losses. Continued capital depletion weakens the company's financial resilience, can raise future financing costs, and may deter strategic partners or investors that prefer counterparties with more stable capital structures.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.60 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$759.05M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 77 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.06.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 161,156,620 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (48.78% Upside)
AU$6.10 (48.78% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(48.78% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
Options Prices
Currently, No data available
---